Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) - Total Liabilities
Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has total liabilities worth CN¥2.37 Billion CNY (≈ $347.09 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600513 cash flow metrics to assess how effectively this company generates cash.
Jiangsu Lianhuan Pharmaceutical Co Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 600513 financial resilience to evaluate the company's liquid asset resilience ratio.
Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saha Pathana Inter-Holding PCL
BK:SPI
|
Thailand | ฿20.74 Billion |
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
China | CN¥383.48 Million |
|
Osisko Development Corp
V:ODV
|
Canada | CA$616.83 Million |
|
Vertex
NASDAQ:VERX
|
USA | $1.01 Billion |
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
USA | $10.31 Billion |
|
Asiana Airline
KO:020560
|
Korea | ₩11.15 Trillion |
|
Longyan Zhuoyue New Energy Co Ltd
SHG:688196
|
China | CN¥781.60 Million |
|
Nesco Limited
NSE:NESCO
|
India | Rs5.54 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Jiangsu Lianhuan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600513 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Lianhuan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual total liabilities of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.44 Billion ≈ $211.05 Million |
+7.76% |
| 2023-12-31 | CN¥1.34 Billion ≈ $195.85 Million |
+2.86% |
| 2022-12-31 | CN¥1.30 Billion ≈ $190.41 Million |
+21.17% |
| 2021-12-31 | CN¥1.07 Billion ≈ $157.14 Million |
+23.85% |
| 2020-12-31 | CN¥867.05 Million ≈ $126.88 Million |
+7.63% |
| 2019-12-31 | CN¥805.57 Million ≈ $117.88 Million |
+70.16% |
| 2018-12-31 | CN¥473.43 Million ≈ $69.28 Million |
+65.39% |
| 2017-12-31 | CN¥286.25 Million ≈ $41.89 Million |
+19.75% |
| 2016-12-31 | CN¥239.03 Million ≈ $34.98 Million |
+5.92% |
| 2015-12-31 | CN¥225.66 Million ≈ $33.02 Million |
+0.43% |
| 2014-12-31 | CN¥224.71 Million ≈ $32.88 Million |
-9.16% |
| 2013-12-31 | CN¥247.36 Million ≈ $36.20 Million |
+166.59% |
| 2012-12-31 | CN¥92.79 Million ≈ $13.58 Million |
+2.07% |
| 2011-12-31 | CN¥90.91 Million ≈ $13.30 Million |
-1.33% |
| 2010-12-31 | CN¥92.13 Million ≈ $13.48 Million |
+2.97% |
| 2009-12-31 | CN¥89.47 Million ≈ $13.09 Million |
+14.74% |
| 2008-12-31 | CN¥77.98 Million ≈ $11.41 Million |
-11.07% |
| 2007-12-31 | CN¥87.69 Million ≈ $12.83 Million |
+14.41% |
| 2006-12-31 | CN¥76.64 Million ≈ $11.22 Million |
+55.03% |
| 2005-12-31 | CN¥49.44 Million ≈ $7.23 Million |
-19.79% |
| 2004-12-31 | CN¥61.63 Million ≈ $9.02 Million |
+31.16% |
| 2003-12-31 | CN¥46.99 Million ≈ $6.88 Million |
+14.56% |
| 2002-12-31 | CN¥41.02 Million ≈ $6.00 Million |
-11.17% |
| 2001-12-31 | CN¥46.18 Million ≈ $6.76 Million |
-4.80% |
| 2000-12-31 | CN¥48.51 Million ≈ $7.10 Million |
-- |
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more